Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

Phase 1positiveENV-105Positive

AI Analysis

Summary

Kairos Pharma reported positive interim safety data from a Phase 1 trial of ENV-105 in EGFR-mutated lung cancer patients, targeting a $10 billion drug resistance market.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Breakthrough interim safety data reported

Importance:5/10

Sentiment:

0.70

Phase 1 datasafety dataEGFR-mutatedlung cancerbreakthrough

Related Companies

$KAPA

Read the original article

Published by yahoo_finance on July 15, 2026 12:30 PM

Read Original